RT Journal Article
SR Electronic
T1 Preparing for Disease X requires CLARITY – Lessons learned from COVID-19 – A systematic Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.27.24317926
DO 10.1101/2024.11.27.24317926
A1 Boivin, Michael
A1 Bourbeau, Jean
A1 Sedeno, Maria
A1 Horvat, Emily
A1 Li, Pei-Zhi
A1 Noueihed, Baraa
A1 Connelly, Kim A.
A1 Jain, Akshay B.
A1 Lin, Peter
A1 Mazer, Bruce D.
A1 Saposnik, Gustavo
A1 Strain, William D.
YR 2024
UL http://medrxiv.org/content/early/2024/11/28/2024.11.27.24317926.abstract
AB Objectives The COVID-19 pandemic has highlighted the critical need for comprehensive preparedness strategies for future pandemics, particularly those caused by unknown pathogens, or Disease X.Study Design Our systematic review examined current literature on COVID-19 risk factors, identifying significant gaps and inconsistencies in data reporting.Methods A systematic literature search was conducted including all English language published retrospective and prospective observational studies which documented clinical outcomes of COVID-19 in adult patients, on Ovid MEDLINE(R) and Epub databases (December 2019 to March 2023).Results The search yielded 440 articles of which 29 were included in the systematic review. We identified major risk factors for severe outcomes. However, inconsistencies in reporting comorbidities, age, disease control levels, medication use, vaccination status, and variant type, limited our analysis. In many publications, this information was not included. Additionally, variations in public attitudes, knowledge, and behaviours regarding COVID-19 vaccines further complicated resource distribution. We propose the CLARITY model to address these gaps by standardizing risk factor reporting, encompassing detailed comorbidity profiles, disease control metrics, age analyses, medication and vaccination data, and variant-specific information.Conclusions Implementing the CLARITY model could improve preparedness and response strategies for Disease X, enabling healthcare professionals and systems to allocate resources more effectively and mitigate the impact of future pandemics. This review underscores the necessity for a coordinated global effort to enhance pandemic preparedness through improved data reporting and risk stratification.Funding This study received financial support from Moderna Biopharma Canada Corporation.Trial Registration PROSPERO Identifier CRD42023449647Competing Interest StatementBoivin has received payment or honoraria from Teva, Pfizer, Novo Nordisk, mdBriefcase, J & J, Abbvie, Astra Zeneca, Boehringer Ingelheim, Moderna, Canopy, Valneva, and Abbott Diabetes and participated on advisory board for Novo-Nordisk, Emergent BioSolutions, Pfizer, Novavax, and GSK. Bourbeau has received grants or contracts from Canadian Institute of Heath Research (CIHR), Reseau en sante respiratoire du FRQS, McGill University, McGill University Health Centre Foundation, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Grifols, Novartis, Sanofi, and Trudell Canada Ltd and has had payment or honoraria from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Pfizer Canada Ltd, Trudell Canada Ltd, and COVIS Pharma Canada Ltd. Connelly has received grants or contracts from Pfizer, AstraZeneca, Boehringer Ingelheim, Servier, Novo Nordisk, Merck, Novartis, and Amgen, payment or honoraria from Pfizer, AstraZeneca, and Boehringer Ingelheim, payment for expert testimony from Servier, Novo Nordisk, and Merck, support for attending meetings from Novartis and Amgen, and patents planned, issued or pending from Boehringer Ingelheim. Jain has received consulting fees from Abbott, Acerus, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Partners in Progressive Medical Education, PocketPills, Sanofi Aventis, and Takeda and payment or honoraria from Abbott, Acerus, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, HLS Therapeutics, Janssen, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, Sanofi Aventis, Timed Right, and WebMD. Lin has received payment or honoraria from Moderna, Pfizer, and AstraZeneca. Mazer holds a leadership or fiduciary role with the COVID-19 Immunity Task Force, Public Health Agency of Canada. Horvat and Sedeno are employees of Respiplus and Bourbeau is an administrator of Respiplus. Respiplus is a non-profit society who received a grant from Moderna Biopharma Canada Corporation for this publication. Boivin, Connelly, Jain, Li, Lin, Mazer, Noueihed, Saposnik, and Strain have received honoraria from Respiplus. Noueihed, Li, Horvat, Saposnik, and Sedeno have no additional conflict to disclose. Strain has received consulting fees from Pfizer, payment or honoraria from Moderna, Pfizer, and AstraZeneca, payment for testimony from NICE, and holds a leadership or fiduciary role with the British Medical Association.Funding StatementThis study received financial support from Moderna Biopharma Canada Corporation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.